
Yunsoo Kim
Examiner (ID: 420, Phone: (571)272-3176 , Office: P/1644 )
| Most Active Art Unit | 1644 |
| Art Unit(s) | 1644, 1641 |
| Total Applications | 1260 |
| Issued Applications | 632 |
| Pending Applications | 154 |
| Abandoned Applications | 508 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19622868
[patent_doc_number] => 12161660
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-12-10
[patent_title] => Nano-sized chitosan/VS
[patent_app_type] => utility
[patent_app_number] => 18/507324
[patent_app_country] => US
[patent_app_date] => 2023-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 3242
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18507324
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/507324 | Nano-sized chitosan/VS | Nov 12, 2023 | Issued |
Array
(
[id] => 19411771
[patent_doc_number] => 12077578
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-03
[patent_title] => Compositions and methods for treating synucleinopathies
[patent_app_type] => utility
[patent_app_number] => 18/341437
[patent_app_country] => US
[patent_app_date] => 2023-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 46704
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18341437
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/341437 | Compositions and methods for treating synucleinopathies | Jun 25, 2023 | Issued |
Array
(
[id] => 18806970
[patent_doc_number] => 20230381303
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 18/324097
[patent_app_country] => US
[patent_app_date] => 2023-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76906
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18324097
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/324097 | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof | May 24, 2023 | Issued |
Array
(
[id] => 18986294
[patent_doc_number] => 20240058263
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => FORMULATIONS OF ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 18/199675
[patent_app_country] => US
[patent_app_date] => 2023-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4034
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18199675
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/199675 | FORMULATIONS OF ANTIBODY | May 18, 2023 | Pending |
Array
(
[id] => 18739591
[patent_doc_number] => 20230348548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => MEMBRANE-BOUND IL-15, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/309080
[patent_app_country] => US
[patent_app_date] => 2023-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 107221
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18309080
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/309080 | MEMBRANE-BOUND IL-15, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF | Apr 27, 2023 | Pending |
Array
(
[id] => 19457716
[patent_doc_number] => 12098196
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-24
[patent_title] => Production of biosimilar ustekinumab in CHO cells
[patent_app_type] => utility
[patent_app_number] => 18/305919
[patent_app_country] => US
[patent_app_date] => 2023-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10430
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 203
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18305919
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/305919 | Production of biosimilar ustekinumab in CHO cells | Apr 23, 2023 | Issued |
Array
(
[id] => 19105825
[patent_doc_number] => 11958906
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Pharmaceutical compositions of mosunetuzumab and methods of use
[patent_app_type] => utility
[patent_app_number] => 18/300064
[patent_app_country] => US
[patent_app_date] => 2023-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 24
[patent_no_of_words] => 42234
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18300064
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/300064 | Pharmaceutical compositions of mosunetuzumab and methods of use | Apr 12, 2023 | Issued |
Array
(
[id] => 18955186
[patent_doc_number] => 20240043513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA AMYLOID ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/300339
[patent_app_country] => US
[patent_app_date] => 2023-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15520
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18300339
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/300339 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA AMYLOID ANTIBODIES | Apr 12, 2023 | Pending |
Array
(
[id] => 18771174
[patent_doc_number] => 20230365986
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => PEPTIDES THAT BLOCK TRANSMISSION OF ORTHOTOSPOVIRUSES AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/117995
[patent_app_country] => US
[patent_app_date] => 2023-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11511
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18117995
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/117995 | Compositions comprising peptides that block transmission of orthotospoviruses | Mar 5, 2023 | Issued |
Array
(
[id] => 18510079
[patent_doc_number] => 20230226178
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS
[patent_app_type] => utility
[patent_app_number] => 18/176155
[patent_app_country] => US
[patent_app_date] => 2023-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31465
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 188
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176155
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | Feb 27, 2023 | Pending |
Array
(
[id] => 18726153
[patent_doc_number] => 20230340409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => ENGINEERED IMMUNE CELLS WITH PRIMING RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 18/114981
[patent_app_country] => US
[patent_app_date] => 2023-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29821
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18114981
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/114981 | ENGINEERED IMMUNE CELLS WITH PRIMING RECEPTORS | Feb 26, 2023 | Pending |
Array
(
[id] => 18610712
[patent_doc_number] => 20230277442
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => SOLUTION PREPARATION CONTAINING STABILIZED ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 18/174043
[patent_app_country] => US
[patent_app_date] => 2023-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11297
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18174043
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/174043 | SOLUTION PREPARATION CONTAINING STABILIZED ANTIBODY | Feb 23, 2023 | Pending |
Array
(
[id] => 18497426
[patent_doc_number] => 20230220060
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/174572
[patent_app_country] => US
[patent_app_date] => 2023-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18174572
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/174572 | METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE | Feb 23, 2023 | Pending |
Array
(
[id] => 18610723
[patent_doc_number] => 20230277453
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => STABILIZED ANTIBODY PROTEIN SOLUTIONS
[patent_app_type] => utility
[patent_app_number] => 18/111017
[patent_app_country] => US
[patent_app_date] => 2023-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25668
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18111017
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/111017 | STABILIZED ANTIBODY PROTEIN SOLUTIONS | Feb 16, 2023 | Pending |
Array
(
[id] => 18738022
[patent_doc_number] => 20230346929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => Stabilized Formulations Containing Anti-IL-33 Antibodies
[patent_app_type] => utility
[patent_app_number] => 18/105772
[patent_app_country] => US
[patent_app_date] => 2023-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31229
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18105772
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/105772 | Stabilized Formulations Containing Anti-IL-33 Antibodies | Feb 2, 2023 | Pending |
Array
(
[id] => 18436054
[patent_doc_number] => 20230183348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => STABLE ANTIBODY FORMULATION
[patent_app_type] => utility
[patent_app_number] => 18/162791
[patent_app_country] => US
[patent_app_date] => 2023-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30098
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -67
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162791
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/162791 | STABLE ANTIBODY FORMULATION | Jan 31, 2023 | Pending |
Array
(
[id] => 19104691
[patent_doc_number] => 11957764
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Protein-type nanoparticles, preparation methods, and application thereof
[patent_app_type] => utility
[patent_app_number] => 18/161036
[patent_app_country] => US
[patent_app_date] => 2023-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 8995
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18161036
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/161036 | Protein-type nanoparticles, preparation methods, and application thereof | Jan 26, 2023 | Issued |
Array
(
[id] => 18752501
[patent_doc_number] => 20230355758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => Pharmaceutical Formulations
[patent_app_type] => utility
[patent_app_number] => 18/152872
[patent_app_country] => US
[patent_app_date] => 2023-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12559
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18152872
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/152872 | Pharmaceutical Formulations | Jan 10, 2023 | Pending |
Array
(
[id] => 19242029
[patent_doc_number] => 12012448
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-18
[patent_title] => High concentration anti-C5 antibody formulations
[patent_app_type] => utility
[patent_app_number] => 18/086031
[patent_app_country] => US
[patent_app_date] => 2022-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 53
[patent_figures_cnt] => 53
[patent_no_of_words] => 44010
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18086031
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/086031 | High concentration anti-C5 antibody formulations | Dec 20, 2022 | Issued |
Array
(
[id] => 18610928
[patent_doc_number] => 20230277658
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING
[patent_app_type] => utility
[patent_app_number] => 18/054101
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30067
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054101
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054101 | COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING | Nov 8, 2022 | Abandoned |